珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Phase III Studies to Investigate Survodutide for People Living with Obesity and Overweight, with and without Diabetes, Cardiovascular Disease and Chronic Kidney Disease
2023年10月09日 17:46:43来源:作者:

SYNCHRONIZE-1 and SYNCHRONIZE-2 are global Phase III studies of survodutide (BI 456906) in people living with obesity and overweight without and with type 2 diabetes, respectively
A third study, SYNCHRONIZE-CVOT, is a global, long-term cardiovascular safety study of survodutide in people living with obesity and overweight with cardiovascular disease, chronic kidney disease or with risk factors for cardiovascular disease
The Phase III studies will soon open for recruitment and include a longer overall treatment period and a higher maximum dose for maintenance treatment compared with Phase II

INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Zealand Pharma A/S (NASDAQ: ZEAL) announced the initiation of three Phase III trials investigating survodutide (also known as BI 456906) for people living with overweight or obesity. The trial design builds upon learnings from Phase II, in which people living with overweight or obesity achieved up to 19 percent weight loss.1 The Phase III trials will soon open for recruitment.

Additional Phase II data, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD), demonstrated reductions in absolute waist circumference (up to 16.0 cm), absolute body weight (up to 19.5 kg) and absolute systolic and diastolic blood pressure (up to 8.6 mmHg and 4.8 mmHg, respectively) over 46 weeks.2

“As the prevalence of the disease of obesity continues to increase,3 it is imperative that we develop additional innovative approaches to address this serious, chronic disease,” said Carel le Roux, M.D., Ph.D., Professor at University College in Dublin, Ireland, and Principal Investigator of the trial. “Survodutide has a novel mechanism of action with the potential to reduce appetite while increasing liver energy expenditure.4 The promising Phase II data give us reason to be hopeful about the potential of survodutide as a treatment for people living with the disease of obesity.4”

SYNCHRONIZE-1 (NCT06066515) and SYNCHRONIZE-2 (NCT06066528), now listed on clinicaltrials.gov, are Phase III studies investigating survodutide in people with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with comorbidities, including dyslipidemia, hypertension and obstructive sleep apnea. SYNCHRONIZE-1 will enroll people without type 2 diabetes (A1C <6.5%) and SYNCHRONIZE-2 will enroll people with type 2 diabetes (A1C ≥6.5%, <10%).

For both studies, the primary endpoints are percent change in body weight at week 76 and the proportion of people who achieve body weight loss of 5% or more at week 76. Secondary endpoints include body weight reductions of at least 10%, 15% and 20% at week 76. A total of 600 participants will be enrolled in each of the two studies, randomized to receive weekly subcutaneous injections of either survodutide, reaching a maximum dose of 3.6 mg or 6.0 mg for maintenance treatment, or placebo.

The third study, SYNCHRONIZE-CVOT, is a Phase III trial that will enroll people with overweight or obesity with cardiovascular disease, chronic kidney disease, or risk factors for cardiovascular disease. In SYNCHRONIZE-CVOT, the primary endpoint is the time to first occurrence of any one of five major adverse cardiac events (5P-MACE): death, non-fatal stroke, non-fatal myocardial infarction, ischemia-related coronary revascularization and heart failure events.

“By implementing the valuable insights gained from the Phase II study, we are confident in the accelerated development of survodutide,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “Obesity is a chronic disease associated with serious health complications that affects hundreds of millions worldwide.5 With these trial initiations, we continue to build on our heritage of bringing differentiated and innovative treatments to address cardiovascular, renal, and metabolic diseases.”

“We are excited that survodutide will shortly enter Phase III trials through the global SYNCHRONIZE program for people living with overweight or obesity,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma. “With novel peptide therapeutics like survodutide, we are targeting key metabolic pathways, and these therapies have the potential to address one of the most significant healthcare challenges in medicine today.”

Please click on the following link for ‘Notes to editors’ and ‘References’:

https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-3-studies-survodutide-obesity-and-overweight

责任编辑: admin

看新闻,关注新闻

天猫网友:Rainy°伤情
评论:这世界上最爱我的男人,早已经从了妈妈。

百度网友:失魂人*pugss
评论:有一天,全世界都不要你了。不要慌,来找我,我会告诉你,我也不要你。

本网网友:ミ支离破碎
评论:谁说我胖我跟谁急,我不就是有点肿么。

搜狐网友:时光安好moon
评论:我也想做一个优雅的淑女,是生活把老娘逼成了泼妇.

网易网友:厮守°- Michae
评论:如果有人和你说:不要脸。你可以对他说:对你根本不需要有脸!

其它网友:苏素/mmmmm
评论:我能想到最浪漫的事,就是看你一起慢慢变老,而我依然青春年少.

腾讯网友:老妹干啥子呢
评论:男人有了烟,有了啤酒,也就有了故事;女人有了钱,有了姿色,也就有了悲剧

天涯网友:血统 FackEdison◎
评论:当有人装B的时候、哥总是低下头。不是哥感到羞愧、而是哥在找砖头.

淘宝网友:迷°Corrid丶
评论:警察说:"你不知道开车不让打电话吗?"我一脸疑惑的说:"我没打电话呀?.....我发短信来着!"

凤凰网友:没你妈娇柔 -   
评论:我的兴趣爱好可分为静态和动态两种,静态就是睡觉,动态就是翻身

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!